Related Experiment Video
Updated: Mar 24, 2026
Thermal Ablation for the Treatment of Abdominal Tumors
Published on: March 7, 2011
Repeat cytoreductive surgery with hyperthermic intraperitoneal chemotherapy: review of indications and outcomes
Harveshp Mogal1, Konstantinos Chouliaras1, Edward A Levine1
1Division of Surgical Oncology, Department of General Surgery, Wake Forest University, Winston-Salem, NC, USA.
Abstract:
Cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) is an established treatment option in selected patients with peritoneal dissemination from a variety of epithelial primaries. Even though a small proportion will be alive and potentially cured at 10 years, the majority will eventually develop recurrent disease. Repeat CRS/HIPEC is a valid consideration in a selected subpopulation of patients with isolated peritoneal recurrence. This review summarizes the data on patient selection, feasibility, limitations and outcomes of repeat CRS/HIPEC.
